CN110200961B - Application of epigallocatechin gallate in preparation of preparation for preventing and/or treating porcine epidemic diarrhea virus - Google Patents
Application of epigallocatechin gallate in preparation of preparation for preventing and/or treating porcine epidemic diarrhea virus Download PDFInfo
- Publication number
- CN110200961B CN110200961B CN201910660522.7A CN201910660522A CN110200961B CN 110200961 B CN110200961 B CN 110200961B CN 201910660522 A CN201910660522 A CN 201910660522A CN 110200961 B CN110200961 B CN 110200961B
- Authority
- CN
- China
- Prior art keywords
- porcine epidemic
- epidemic diarrhea
- diarrhea virus
- cells
- epigallocatechin gallate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of epigallocatechin gallate in preparation of a preparation for preventing and/or treating porcine epidemic diarrhea virus, and relates to the technical field of antiviral application. The epigallocatechin gallate (EGCG) provided by the invention can effectively inhibit the adsorption, encytosis, replication, assembly and release of the porcine epidemic diarrhea virus, thereby inhibiting the infection of the porcine epidemic diarrhea virus, and the EGCG can also directly kill the porcine epidemic diarrhea virus, thereby being used for treating the porcine epidemic diarrhea disease.
Description
Technical Field
The invention relates to the technical field of antiviral application, in particular to application of epigallocatechin gallate in preparation of a preparation for preventing and/or treating porcine epidemic diarrhea virus.
Background
Porcine Epidemic Diarrheal (PED) is a highly contagious enteric infectious disease of pigs caused by Porcine Epidemic Diarrhea Virus (PEDV), and is mainly characterized by vomiting, diarrhea and decreased appetite. Pigs of all ages are susceptible to the disease, the incidence rate of suckling pigs, skeleton pigs and fattening pigs is up to 100%, 100% of piglets at 10 days are dead, and the fattening pigs grow slowly and lose weight. In recent years, the disease is epidemic in a plurality of countries all over the world, the disease death rate is extremely high, and huge economic loss is caused to the pig raising industry.
Porcine epidemic diarrhea virus is a single-stranded positive-strand RNA virus, enveloped, member of the genus Coronavir (Coronavir) belonging to the family Coronaviridae (Nidovirales) family Coronaviridae (Coronavir). Porcine Epidemic Diarrhea Virus (PEDV) was found to infect porcine cells, human cells, monkey cells and bat cells. Although, no example of human infection with porcine epidemic diarrhea virus has been found clinically. However, coronaviruses are important pathogens for infecting humans and animals, and there is a great risk to the health of humans and animals. The S gene of porcine epidemic diarrhea virus plays a significant role in the processes of virus adsorption and fusion with host cells, and plays an important role in host chemotaxis. Moreover, the S gene is easy to mutate, so that the host of the virus can be changed, new species can be infected, transmission among different species can occur, and cross-species infection risks occur, thereby threatening the health of human beings.
In order to reduce economic loss caused by porcine epidemic diarrhea and protect human and animal health, the prior art mostly adopts a vaccine immunization means for prevention and is assisted with health management and medication. Currently, no specific medicine or treatment is available for porcine epidemic diarrhea.
Disclosure of Invention
In view of the above, the present invention aims to provide an application of epigallocatechin gallate in preparation of a preparation for preventing and/or treating porcine epidemic diarrhea virus. The epigallocatechin gallate (EGCG) provided by the invention can effectively inhibit the adsorption, encytosis, replication, assembly and release of the porcine epidemic diarrhea virus, thereby inhibiting the infection of the porcine epidemic diarrhea virus, and the EGCG can also directly kill the porcine epidemic diarrhea virus, thereby being used for treating the porcine epidemic diarrhea disease.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides application of epigallocatechin gallate in preparation of a preparation for preventing and/or treating porcine epidemic diarrhea virus.
Preferably, the epigallocatechin gallate is used for preventing and/or treating porcine epidemic diarrhea virus by inhibiting the absorption of porcine epidemic diarrhea virus.
Preferably, the epigallocatechin gallate is used for preventing and/or treating porcine epidemic diarrhea virus by inhibiting the porcine epidemic diarrhea virus from entering cells.
Preferably, the epigallocatechin gallate is used for preventing and/or treating porcine epidemic diarrhea virus by inhibiting the replication of porcine epidemic diarrhea virus.
Preferably, the epigallocatechin gallate is used for preventing and/or treating porcine epidemic diarrhea virus by inhibiting the assembly of porcine epidemic diarrhea virus.
Preferably, the epigallocatechin gallate is used for preventing and/or treating porcine epidemic diarrhea virus by inhibiting the release of porcine epidemic diarrhea virus.
Preferably, the epigallocatechin gallate can directly kill the porcine epidemic diarrhea virus to prevent and/or treat the porcine epidemic diarrhea virus.
Preferably, the preparation comprises a drug, a feed additive, a disinfectant and a derivative prepared with epigallocatechin gallate as a backbone.
The invention provides application of epigallocatechin gallate in preparing a preparation for preventing and/or treating porcine epidemic diarrhea virus, and compared with the prior art, the epigallocatechin gallate has the following advantages:
the epigallocatechin gallate provided by the invention has a very obvious effect on resisting the porcine epidemic diarrhea virus infection, EGCG can reduce cytopathy caused by the porcine epidemic diarrhea virus, inhibit the adsorption, encytosis, assembly and release of the porcine epidemic diarrhea virus, and can directly kill the porcine epidemic diarrhea virus, thereby providing a scientific and reliable theoretical basis for clinical treatment of the porcine epidemic diarrhea.
Drawings
FIG. 1 is a microscopic image showing the effect of epigallocatechin-3-gallate on porcine epidemic diarrhea virus-induced cytopathic effects;
FIG. 2 is a graph of the inhibition of PEDV infection by epigallocatechin gallate (EGCG), wherein A and B are Western blot to detect the effect of epigallocatechin-3-gallate on the expression level of structural protein N of porcine epidemic diarrhea virus in Vero cells; c, detecting the titer of the porcine epidemic diarrhea virus in the cell supernatant by using a plaque forming test;
FIG. 3 is a graph of Western blot to determine the effect of epigallocatechin-3-gallate on porcine epidemic diarrhea virus adsorption on Vero cells;
FIG. 4 is a graph of Western blot to determine the effect of epigallocatechin-3-gallate on porcine epidemic diarrhea virus entry on Vero cells;
FIG. 5 is a graph of Western blot to determine the effect of epigallocatechin-3-gallate on porcine epidemic diarrhea virus replication on Vero cells;
FIG. 6 is a graph of qRT-PCR assay of the effect of epigallocatechin-3 gallate on porcine epidemic diarrhea virus assembly on Vero cells;
FIG. 7 is a graph of a plaque formation assay measuring the effect of epigallocatechin-3-gallate on porcine epidemic diarrhea virus release on Vero cells;
FIG. 8 is a graph showing the results of Western blot analysis of the direct killing effect of epigallocatechin-3-gallate on porcine epidemic diarrhea virus.
Detailed Description
The invention provides application of epigallocatechin gallate in preparation of a preparation for preventing and/or treating porcine epidemic diarrhea virus.
In the present invention, the epigallocatechin gallate is also referred to as epigallocatechin-3-gallate or epigallocatechin gallate. The source of epigallocatechin-3-gallate is not particularly limited in the present invention, and conventional commercial products can be used, and preferably, the epigallocatechin-3-gallate is purchased from selelck. In the embodiment of the present invention, the porcine epidemic diarrhea virus is preferably an HLJBY strain, which is obtained by using a conventional commercially available product.
In the present invention, the epigallocatechin gallate plays a role in resisting viral infection by inhibiting the porcine epidemic diarrhea virus from being adsorbed to cells.
In the present invention, the epigallocatechin gallate plays a role in resisting viral infection by inhibiting the invasion of porcine epidemic diarrhea virus.
In the present invention, the epigallocatechin gallate plays a role in resisting viral infection by inhibiting the replication of porcine epidemic diarrhea virus in cells.
In the present invention, the epigallocatechin gallate plays a role in resisting viral infection by inhibiting the assembly of porcine epidemic diarrhea virus in cells.
In the present invention, the epigallocatechin gallate plays a role in resisting viral infection by inhibiting the release of porcine epidemic diarrhea virus in cells.
In the present invention, the epigallocatechin gallate directly kills porcine epidemic diarrhea virus and thus plays a role in resisting viral infection.
In the present invention, the preparation preferably comprises a drug, a feed additive, a disinfectant and a derivative prepared with epigallocatechin gallate as a backbone.
In the present invention, when the preparation is preferably a drug, the epigallocatechin gallate preferably accounts for 1% to 99% of the total mass of the drug. The invention has no special limitation on the auxiliary materials of the medicine, and the corresponding auxiliary materials are preferably selected through the dosage form of the medicine.
In the present invention, when the preparation is preferably a feed additive, the epigallocatechin gallate preferably accounts for 1% to 99% of the total mass of the feed additive. The auxiliary materials of the feed additive are not particularly limited, and the auxiliary materials of the conventional feed additive are preferably adopted.
In the present invention, when the preparation is preferably a disinfectant, the epigallocatechin gallate preferably accounts for 1% to 99% of the total mass of the disinfectant. The auxiliary materials of the disinfectant are not particularly limited, and the auxiliary materials for preparing the disinfectant by a conventional method are preferably adopted.
The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Effect of Epigallocatechin-3-gallate on cytopathic effects of porcine epidemic diarrhea Virus
Vero cells were diluted with a nutrient solution containing 8% fetal bovine serum and counted, and 5X 10 cells were added5Cells at a concentration per well were plated in six well plates and placed in a chamber containing 5% CO237 ℃ incubator. After the cells grow to a density of 70-80% (about 16h), washing the cells twice by using a PBS solution, respectively pretreating the cells for 1h by using PBS or EGCG (20 mu M,50 mu M and 100 mu M), then infecting the cells by using a porcine epidemic diarrhea virus HLJBY strain (0.1MOI), changing the solution after 1h, infecting for 24h and keeping the drug, and observing the morphological change and pathological change of the cells under a microscope, wherein the figure is 1. As shown in FIG. 1, EGCG reduced cytopathic effects of porcine epidemic diarrhea virus.
Example 2
Influence of epigallocatechin-3-gallate on the expression level of structural protein N of porcine epidemic diarrhea virus in cells and influence of virus titer in supernatant
Vero cells were diluted with a nutrient solution containing 8% fetal bovine serum and counted, and 5X 10 cells were added5Cells at a concentration per well were plated in six well plates and placed in a chamber containing 5% CO237 ℃ incubator. After the cells grow to a density of 70-80% (about 16h), washing the cells twice by using a PBS solution, respectively pretreating the cells for 1h by using PBS or EGCG (50 mu M), then infecting the cells by using a porcine epidemic diarrhea virus HLJBY strain (0.1MOI), changing the solution after 1h, infecting for 4h, 8h, 12h, 24h and 36h, and continuously existence of the medicine, collecting protein samples of the cells, and analyzing the change of the structural protein N expression level of the porcine epidemic diarrhea virus by using Western blot. Cell treatment cells were pretreated with PBS or EGCG (20. mu.M, 50. mu.M, 100. mu.M), respectively, for 1h, then infected with porcine epidemic diarrhea virus HLJBY strain (0.1MOI), and after 1h, the cells were changed and infected for 24h with the drug present, and the cell supernatant was first collected and the titer change of the virus in the supernatant was examined by plaque formation assay, as described above. The cells were washed three times with PBS solution, protein samples of the cells were collected, and changes in the expression level of structural protein N of porcine epidemic diarrhea virus were analyzed using Western blot, as shown in FIG. 2. As shown in figure 2, EGCG can significantly reduce the expression of the protein level of the porcine epidemic diarrhea virus structural protein N in Vero cells. Simultaneously, EGCG also reduced the supernatantThe virus titer in (1).
Example 3
Effect of Epigallocatechin-3-gallate on the Process of porcine epidemic diarrhea Virus infection
(1) Effect of Epigallocatechin-3-gallate on the adsorption of porcine epidemic diarrhea Virus (Western blot)
Vero cells were diluted with a nutrient solution containing 8% fetal bovine serum and counted, and 5X 10 cells were added5Cells at a concentration per well were plated in six well plates and placed in a chamber containing 5% CO237 ℃ incubator. After the cells grow to a density of 70-80% (about 16h), the cells are washed three times by PBS solution, the cells are respectively pretreated for 1h by PBS or EGCG (20 mu M,50 mu M and 100 mu M), then the cells are infected by porcine epidemic diarrhea virus HLJBY strain (0.1MOI), the cells are placed in a refrigerator at 4 ℃ for incubation for 1h, the cells are washed three times by cold PBS, changed into 2% DMEM, placed in an incubator at 37 ℃, cell protein samples are collected after 24h, and the expression condition of the N protein level of the virus protein is detected, which is shown in figure 3. As can be seen from fig. 3, EGCG significantly inhibited the adsorption of porcine epidemic diarrhea virus.
(2) Effect of Epigallocatechin-3-gallate on porcine epidemic diarrhea Virus encytosis (Western blot)
Vero cells were diluted with a nutrient solution containing 8% fetal bovine serum and counted, and 5X 10 cells were added5Cells at a concentration per well were plated in six well plates and placed in a chamber containing 5% CO237 ℃ incubator. After the cells grow to 70-80% density (about 16h), infecting the cells with porcine epidemic diarrhea virus HLJBY strain (0.1MOI) at 4 ℃ for 1h, washing the cells three times with cold PBS solution, treating the cells with PBS or EGCG (20 mu M,50 mu M and 100 mu M) respectively, placing the cells in an incubator at 37 ℃ for 1h, washing the cells three times with citric acid water and PBS respectively, after infecting for 24h, collecting cell protein samples, and detecting the expression of the protein level of the virus protein N, which is shown in figure 4. As can be seen from FIG. 4, EGCG significantly inhibited the entry process of porcine epidemic diarrhea virus.
(3) Effect of Epigallocatechin-3-gallate on replication of porcine epidemic diarrhea Virus (Western blot)
Vero cells were diluted with a nutrient solution containing 8% fetal bovine serum and counted, and 5X 10 cells were added5Cells at a concentration per well were plated in six well plates and placed in a chamber containing 5% CO237 ℃ incubator. After the cells grow to the density of 70-80% (about 16h), washing the cells for three times by using a PBS (phosphate buffer solution), infecting porcine epidemic diarrhea virus (0.1MOI), changing the solution after 1h, adding a PBS or EGCG (50 mu M) solution for treatment, collecting cell protein samples after 4h and 6h of virus infection, and detecting the influence of EGCG on the expression level of structural protein N of the porcine epidemic diarrhea virus by using Western blot, wherein the expression level is shown in figure 5. As can be seen from fig. 5, EGCG can reduce the expression level of structural protein N of porcine epidemic diarrhea virus and significantly inhibit the replication of porcine epidemic diarrhea virus.
(4) Effect of Epigallocatechin-3-gallate on porcine epidemic diarrhea Virus Assembly (qRT-PCR)
Vero cells were diluted with a nutrient solution containing 8% fetal bovine serum and counted, and 5X 10 cells were added5Cells at a concentration per well were plated in six well plates and placed in a chamber containing 5% CO237 ℃ incubator. After the cells grow to a density of 70-80% (about 16h), the cells are washed three times with PBS solution, infected with porcine epidemic diarrhea virus (0.1MOI), and the solution is changed after 1h, and treated with PBS or EGCG (20. mu.M and 50. mu.M) solution. After 24h of virus infection, cell supernatants were collected and treated with Trizol, the cells were washed three times with PBS, treated with Trizol, total RNA in the cell supernatants and cells were extracted and reverse-transcribed to synthesize cDNA, and the expression level of ORF3 gene in the cell supernatants and cells was quantitatively determined by fluorescence, as shown in FIG. 6. As can be seen in fig. 6, EGCG significantly inhibited the porcine epidemic diarrhea virus assembly process.
(5) Effect of Epigallocatechin-3-gallate on porcine epidemic diarrhea Virus Release (plaque formation assay)
Vero cells were diluted with a nutrient solution containing 8% fetal bovine serum and counted, and 5X 10 cells were added5Cells at a concentration per well were plated in six well plates and placed in a chamber containing 5% CO237 ℃ incubator. After the cells grow to a density of 70-80% (about 16h), the cells are washed three times with PBS solution, infected with porcine epidemic diarrhea virus (0.1MOI), and the solution is changed after 1h, and treated with PBS or EGCG (20. mu.M and 50. mu.M) solution. 24h after viral infection, cell supernatants were first collected and then washed three times with PBS solution to eachAdding 1mL of serum-free nutrient solution into the air, repeatedly freezing and thawing for 2-3 times, and collecting the solution into an EP tube. The titer of porcine epidemic diarrhea virus in cell supernatants and cells was measured by plaque formation assay, see figure 7. As can be seen from fig. 7, EGCG significantly inhibited the release of porcine epidemic diarrhea virus.
(6) Direct killing effect of epigallocatechin-3-gallate on porcine epidemic diarrhea virus (Western blot)
PBS or EGCG (50. mu.M and 100. mu.M) solution was incubated with PEDV for 1h at 37 ℃, then Vero 1h was inoculated, washed three times with PBS and replaced with 2% DMEM, protein samples were collected after 24h, and the level of structural protein N expression of porcine epidemic diarrhea virus was detected using western blot, see FIG. 8. As can be seen in FIG. 8, EGCG directly killed porcine epidemic diarrhea virus.
The results of examples 1 to 3 show that EGCG can reduce cytopathic effect caused by porcine epidemic diarrhea virus, inhibit the adsorption, encytosis, assembly and release of porcine epidemic diarrhea virus, and directly kill porcine epidemic diarrhea virus.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (8)
1. Application of epigallocatechin gallate in preparing preparation for preventing and/or treating porcine epidemic diarrhea virus is provided.
2. The use according to claim 1, wherein the epigallocatechin gallate is used for the prevention and/or treatment of porcine epidemic diarrhea virus by inhibiting its adsorption.
3. The use according to claim 1, wherein the epigallocatechin gallate is used for the prevention and/or treatment of porcine epidemic diarrhea virus by inhibiting its entry into the cell.
4. The use according to claim 1, wherein the epigallocatechin gallate is used for the prevention and/or treatment of porcine epidemic diarrhea virus by inhibiting its replication.
5. The use according to claim 1, wherein the epigallocatechin gallate is used for the prevention and/or treatment of porcine epidemic diarrhea virus by inhibiting the assembly of porcine epidemic diarrhea virus.
6. The use according to claim 1, wherein the epigallocatechin gallate is used for the prevention and/or treatment of porcine epidemic diarrhea virus by inhibiting the release of porcine epidemic diarrhea virus.
7. The use according to claim 1, wherein the epigallocatechin gallate is capable of directly killing porcine epidemic diarrhea virus to prevent and/or treat porcine epidemic diarrhea virus.
8. Use according to claim 1, wherein the formulation comprises a medicament, a feed additive, a disinfectant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910660522.7A CN110200961B (en) | 2019-07-22 | 2019-07-22 | Application of epigallocatechin gallate in preparation of preparation for preventing and/or treating porcine epidemic diarrhea virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910660522.7A CN110200961B (en) | 2019-07-22 | 2019-07-22 | Application of epigallocatechin gallate in preparation of preparation for preventing and/or treating porcine epidemic diarrhea virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110200961A CN110200961A (en) | 2019-09-06 |
| CN110200961B true CN110200961B (en) | 2021-07-27 |
Family
ID=67797857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910660522.7A Active CN110200961B (en) | 2019-07-22 | 2019-07-22 | Application of epigallocatechin gallate in preparation of preparation for preventing and/or treating porcine epidemic diarrhea virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110200961B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112891336A (en) * | 2021-02-01 | 2021-06-04 | 南湖实验室 | Medical application of gallocatechin gallate and derivatives thereof |
| CN113995748B (en) * | 2021-11-17 | 2023-05-02 | 武汉轻工大学 | Application of ellagic acid in preparation of medicines or feed additives for treating or preventing porcine viral diarrhea |
| CN114748459A (en) * | 2021-12-02 | 2022-07-15 | 中国农业大学 | Application of gallic acid in preparing medicine for preventing and treating colibacillosis |
| CN114470209B (en) * | 2022-01-22 | 2023-08-04 | 安徽省农业科学院畜牧兽医研究所 | Application of TRIM2 in preventing and treating porcine epidemic diarrhea virus infection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420695A (en) * | 2016-09-09 | 2017-02-22 | 南京农业大学 | Application of glycyrrhizin in resistance to PEDV (porcine epidemic diarrhea virus) infection |
| CN108514556A (en) * | 2018-07-09 | 2018-09-11 | 南京农业大学 | Purposes of the licochalcone A in preparing porcine epidemic diarrhea resisting virus drugs |
-
2019
- 2019-07-22 CN CN201910660522.7A patent/CN110200961B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420695A (en) * | 2016-09-09 | 2017-02-22 | 南京农业大学 | Application of glycyrrhizin in resistance to PEDV (porcine epidemic diarrhea virus) infection |
| CN108514556A (en) * | 2018-07-09 | 2018-09-11 | 南京农业大学 | Purposes of the licochalcone A in preparing porcine epidemic diarrhea resisting virus drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110200961A (en) | 2019-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110200961B (en) | Application of epigallocatechin gallate in preparation of preparation for preventing and/or treating porcine epidemic diarrhea virus | |
| CN110731958B (en) | Application of EGCG in preparation of preparation for preventing and/or treating PRV infection and preparation for preventing and/or treating PRV infection | |
| CN107287218B (en) | Avian infectious bronchitis virulent strain S1 gene and virulent strain and application thereof | |
| Van Reeth et al. | Porcine respiratory coronavirus-mediated interference against influenza virus replication in the respiratory tract of feeder pigs | |
| CN108514556B (en) | Application of licochalcone A in preparation of medicine for resisting porcine epidemic diarrhea virus | |
| CN108066758B (en) | Raccoon dog canine distemper-parvovirus enteritis bigeminal live vaccine and preparation method and application thereof | |
| CN111073863B (en) | Porcine epidemic diarrhea and porcine delta coronavirus bivalent attenuated vaccine and preparation method thereof | |
| CN113171374B (en) | Application of sea buckthorn polysaccharide in preparation of preparation for preventing and/or treating porcine pseudorabies virus infection | |
| CN113018296B (en) | Application of melatonin in resisting porcine coronavirus | |
| CN114984035A (en) | Application of glycyrrhiza polysaccharide in preparation of preparation for resisting porcine pseudorabies virus infection | |
| CN109419804B (en) | Antiviral plant-derived preparation for livestock and poultry | |
| CN111729091B (en) | Method for checking efficacy of porcine Seika virus inactivated vaccine by using rabbit | |
| CN107828741A (en) | The dual-gene missing low virulent strain of pseudorabies virus and its application | |
| CN108949700B (en) | Goat parainfluenza virus 3 type JS14-2 strain and application thereof | |
| CN107982323B (en) | Application of corydalis tuber in preparing medicine for inhibiting and killing bovine viral diarrhea virus BVDV | |
| CN107854499B (en) | Application of myrobalan in preparing medicine for inhibiting and killing bovine viral diarrhea virus BVDV | |
| CN105039270B (en) | H9N2 subtype avian influenza acclimatization to cold attenuated strains and its application | |
| CN115844879A (en) | Application of melatonin in resisting Galavirus | |
| CN101380470B (en) | Pig parvovirus live vaccine | |
| AU2020100889A4 (en) | An Application Of EGCG In Porcine Epidemic Diarrhea Virus Preparations | |
| CN116083374A (en) | High Wen Ji-resistant salmonella pullorum bacteriophage, bacteriophage composition and application thereof | |
| CN111551747A (en) | Method for testing efficacy of porcine epikavirus inactivated vaccine by using rabbit based on antibody detection | |
| CN109010331B (en) | Application of tea polyphenol in preventing and treating blue ear disease | |
| CN105853406A (en) | Application of procyanidine in preparation of medicine for preventing and treating porcine reproductive and respiratory syndrome | |
| CN112807424A (en) | Bivalent live vaccine for bovine viral diarrhea and bovine infectious rhinotracheitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |